About the book
Malignant tumors consist of various cancer cell types, contributing to tumor heterogeneity. Cancer Stem Cells (CSCs) are a subpopulation of such cells, characterized by the stem cell features (such as self‐renewal, differentiation, and ability to recapitulate the parental tumor upon transplantation into a host). CSCs have been associated with negative clinical outcomes, mostly because of their contribution to cancer initiation, progression, resistance to conventional anticancer therapy (e.g., chemotherapy and radiation therapy), metastasis, and recurrence. The aim of this book is to concisely summarize current and emerging research efforts focused on CSCs, as potential diagnostic and therapeutic targets, for improving the outcomes patients with the most refractory cancers. This overview will highlight an impact of Mesenchymal Stem Cells (MSCs) (a population of CSCs that can differentiate into mesodermal cells) on the tumor development and progression, via their effects on Epithelial‐to‐Mesenchymal Transition (EMT), angiogenesis, resistance to treatment, and metastatic spread. Furthermore, since MSCs may also suppress cancer cells, the mechanisms that govern the pro‐and anticancer effects of MSCs will be explained. In addition, this collection will review the key CSC signaling pathways, and some innovative strategies (e.g., targeted therapies, immunotherapy, and epigenetic approaches), aimed at expanding the therapeutic armamentarium for patients with difficult to treat malignancies. This book will also serve as an updated resource for the CSC research community. Hopefully, it will facilitate translation of recent progress in CSCs research into clinical practice, providing some potential solutions to unmet therapeutic needs in oncology.